ESMO 2023 | ARTA drugs: exploring new therapies, ODM 208, and biomarkers

Rob Jones, MD, PhD, The University of Glasgow, Glasgow, UK, discusses the sequencing of Androgen Receptor-Targeted Agents (ARTA) drugs, including enzalutamide, apalutamide, darolutamide, or abiraterone, in the treatment of castration-resistant prostate cancer (CRPC). Current evidence suggests that the sequential use of these drugs is not an effective strategy, with limited clinical benefit. Patients experiencing transient PSA responses, especially when switching from abiraterone to enzalutamide, show minimal overall benefit. Prof. Jones emphasizes the need to consider alternative, more active agents such as chemotherapy, radionuclide therapy, or PARP inhibitors, particularly in cases of resistance to ARTA drugs. He introduces an emerging therapy, ODM-208, a steroid hormone biosynthesis inhibitor designed for patients with mutations in the androgen receptor ligand binding domain. This drug aims to address ligand binding domain mutations, offering a potential treatment avenue for CRPC patients who have progressed on ARTA therapy. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR) 2023 in Malaga, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.